China Securities Intelligence Financial News Kangtai Biological(300601) announced on the evening of September 15 that its wholly-owned subsidiary Beijing Minhai Biotechnology Co., Ltd. received the "Drug Registration Certificate" issued by the State Food and Drug Administration, and its developed Sabin strain inactivated polio vaccine (Vero cell) was officially approved for marketing.
　　According to the announcement, the vaccine is used to prevent acute infectious diseases caused by polio virus. After vaccination, it can stimulate the body to produce immunity against polio virus and is used to prevent poliomyelitis caused by polio type I, II and III virus infection.
　　According to the website of the National Medical Products Administration, the manufacturers of the vaccine currently on the market in China include Beijing Sinovac BiotechProducts Co., Ltd., Beijing Biological ProductsInstitute Co., Ltd., Institute of Medical Biology, Chinese Academy of Medical Sciences.
　　The announcement stated that the approval of the above-mentioned vaccines for marketing will further enrich the company's product lineup, lay a solid foundation for the development of combination vaccines, enhance the company's core competitiveness, strengthen the company's market position, and lay a solid foundation for the company's continued stable development.

https://finance.eastmoney.com/a/202509153513963260.html